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A complete list of centers and investigators participating in the Albumin Italian Outcome Sepsis substudy has been published elsewhere: Masson S, Caironi P, Spanuth E, et al; ALBIOS Study Investigators: Presepsin (soluble CD14 subtype) and procalcitonin levels for mortality prediction in sepsis: Data from the Albumin Italian Outcome Sepsis trial. Crit Care 2014; 18:R6. M yocardial dysfunction is common during sepsis, especially in the subgroup of patients with shock (1-3). As untreated myocardial dysfunction is associated with a poor outcome (1) (2) (3) , early identification of high-risk patients with myocardial dysfunction could reduce mortality. Accordingly, early assessable circulating biomarkers might be crucial to identify high-risk patients with myocardial dysfunction at hospital admission.
Secretoneurin is a 33-amino acid peptide belonging to the granin protein family (4) . In states of myocardial dysfunction, secretoneurin production in neuroendocrine and myocardial tissues is augmented (5, 6) , and secretoneurin seems to regulate important processes in the myocardium (4), including cardiomyocyte Ca 2+ handling (7) . Circulating secretoneurin levels also correlate with cortisol concentrations, established biomarkers of cardiac function, and renal dysfunction in critically ill patients with infections (8) . Although the pathophysiology reflected by secretoneurin as a biomarker requires additional work to be fully established, previous experimental and clinical data therefore support secretoneurin as a biomarker that could integrate information on the complex network of cardiovascular, neuroendocrine, and renal systems. All of these systems are strongly involved in the pathophysiology of sepsis and septic shock and associated with sepsis outcome. We have previously reported that secretoneurin levels at admission provide incremental prognostic information to established risk indices in critically ill patients with infections (8) . Circulating secretoneurin levels also improve risk assessment in patients with acute heart failure, after ventricular arrhythmia-induced cardiac arrest, and in patients with acute respiratory failure due to cardiovascular disease, while not improving prognostication in patients with primary pulmonary-related dyspnea (7, 9) . Hence, secretoneurin is a promising prognostic biomarker in patients primarily with myocardial dysfunction, which could impact also the prognostic ability by secretoneurin in patients with sepsis. Accordingly, by employing biospecimens from the largest cohort of patients with severe sepsis or septic shock currently available, we hypothesized that secretoneurin levels would provide more additional prognostic information to established risk indices in patients with septic shock, who are hemodynamically unstable, than in patients with severe sepsis without shock.
METHODS
Additional information for the Methods section can be found in the online data supplement (Supplemental Digital Content 1, http://links.lww.com/CCM/D316).
The Albumin Italian Outcome Sepsis Study
The Albumin Italian Outcome Sepsis (ALBIOS) trial was a multicenter, pragmatic, open-label, randomized, prospective clinical trial testing fluid administration with either 20% human albumin and crystalloids or crystalloid solutions alone in patients with severe sepsis or septic shock in 100 ICUs in Italy. The total study cohort of the ALBIOS trial included 1,818 patients greater than or equal to 18 years who met clinical criteria for severe sepsis or septic shock within 24 hours from hospital admittance or anytime during the ICU stay (10) . Patients received guideline-based therapy and were randomized to either 20% albumin and crystalloids or crystalloid solutions alone from randomization until day 28 or ICU discharge, whichever came first. The study was conducted according to the Declaration of Helsinki and approved by the institutional Review Board of all participating hospitals. Written informed consent or deferred consent was obtained for all included patients, as granted by the review boards of its participating centers, and according to Italian legislation.
Biomarker Substudy and Laboratory Analyses
For the current substudy, blood samples were available from 958 patients. Blood samples were collected from patients enrolled in 40 of the 100 ICUs that agreed to participate to a predefined biomarkers substudy. Nonetheless, these centers enrolled the majority of the patients randomized in the ALBIOS trial, therefore guaranteeing a representativeness of the disease investigated. Venous blood samples were collected after randomization on days 1, 2, and 7 (or on ICU discharge, whichever came first). Secretoneurin levels were measured in EDTA plasma by an in-house radioimmunoassay in Uppsala, Sweden as previously reported (5, (7) (8) (9) . The secretoneurin assay has a detection limit of 50 pmol/L and a coefficient of variation of 9% in the lower range (110 pmol/L) and 4% in the upper range (380 pmol/L). The assays for N-terminal pro-B-type natriuretic peptide (NT-proBNP) and highly sensitive cardiac troponin T (hs-cTnT) measurements have previously been reported (11) .
Statistical Analysis
Categorical variables were presented as proportions, whereas continuous variables as means (sd) or median (Q1-Q3), as appropriate. Differences across categorical variables were assessed by the chi-square test or the Fisher exact test, and analysis of variance or the nonparametric Kruskal-Wallis test were used for continuous variables. Correlation coefficients were calculated by Spearman rank correlation, and multivariate linear regression analysis was employed to identify variables associated with increasing secretoneurin levels. The association between secretoneurin levels and mortality was tested by the log-rank test across secretoneurin tertiles in Kaplan-Meier plots and by performing univariate and multivariable logistic regression analyses. All variables associated with ICU and 90-day mortality in univariate analysis were included into the multivariable analyses (details in the footnote of Table 1 and in the supplementary material, Statistical Analysis section, Supplemental Digital Content 1, http://links.lww.com/CCM/D316). We also calculated two logistic models for ICU or 90-day mortality with an interaction term between secretoneurin concentration on day 1 and prevalent shock. Prognostic accuracy was tested by calculating the area under the curve (AUC) with 95% CIs based on receiver operating curve statistics, and reclassification was assessed by the category-free net reclassification index (NRI) and presented as recommended for nested models (12, 13) . A p value of less than 0.05 was considered statistically significant.
RESULTS

Secretoneurin Levels in Patients With Severe Sepsis or Septic Shock
Detailed clinical characteristics of the 958 patients with secretoneurin measured on day 1 after randomization are compared with the total ALBIOS cohort in Supplementary Table 1 (Supplemental Digital Content 1, http://links.lww.com/CCM/ D316). In general, there are no major differences between the biomarker substudy population and the total ALBIOS cohort. The median secretoneurin level on day 1 was 201 pmol/L (Q1-Q3, 161-259 pmol/L). When stratifying patients according to secretoneurin tertiles, patients with the highest secretoneurin levels were older, had higher NT-proBNP and hs-cTnT levels and had higher Sequential Organ Failure Assessment (SOFA) and Simplified Acute Physiology (SAPS) II scores (Supplementary Table 2 , Supplemental Digital Content 1, http://links.lww.com/CCM/D316). Several other risk factors in sepsis were also more prevalent in patients with high secretoneurin levels, including chronic renal failure and history of cardiovascular disease, while use of antibiotics or appropriate antibiotic therapy did not differ across secretoneurin tertiles. Secretoneurin levels on day 1 were higher in patients with septic shock (n = 540) compared with patients with severe sepsis without shock (n = 418): 208 pmol/L (167-265 pmol/L) versus 194 pmol/L (158-249 pmol/L), p value equals to 0.002.
Secretoneurin levels on day 1 correlated with several variables, including NT-proBNP and hs-cTnT levels, as well as SOFA and SAPS II scores (Supplementary Table 3 , Supplemental Digital Content 1, http://links.lww.com/CCM/D316). Increasing age and higher serum concentrations of creatinine, bilirubin, lactate, and NT-proBNP levels were all independently associated with high secretoneurin levels on day 1 by multivariable linear regression analysis (Supplementary Table 4 , Supplemental Digital Content 1, http://links.lww.com/CCM/D316). Patients with high secretoneurin levels on day 1 were less likely to achieve hemodynamic goals during the first 6-24 hours compared with patients with lower secretoneurin levels, even though they received more often vasoactive drugs (Supplementary Table 5 , Supplemental Digital Content 1, http://links.lww.com/CCM/ D316). Secretoneurin levels on day 1 differed significantly across quintiles of SOFA score, including all organ-specific subscores but for the respiratory component ( Supplementary Fig. 1 , Supplemental Digital Content 1, http://links.lww.com/CCM/ D316). There was no difference in secretoneurin levels on day 1 between patients randomized to albumin (n = 474) and crystalloids 
Secretoneurin Levels on Day 1 and ICU and 90-Day Mortality With Patients Stratified According to Shock
ICU mortality was 29% (159/540) among patients with septic shock and 23% (94/418) among patients with severe sepsis without shock, whereas 90-day mortality was 44% (234/536) in septic shock and 33% (135/409) in patients with severe sepsis without shock. We assessed the associations between secretoneurin levels, stratified by tertiles, and mortality in patients with septic shock and severe sepsis without shock separately: secretoneurin on day 1 was associated with ICU and 90-day mortality in patients with septic shock, and only 90-day mortality in those with severe sepsis without shock (Fig. 1) . Secretoneurin levels on day 1 also remained associated with both ICU and 90-day mortality in patients with septic shock, both when adjusting for clinical variables and established risk scores (Table 1 , Model number 1), as well as after further addition of NT-proBNP and hs-cTnT levels to the previous models (Model number 2). In contrast, the association between day 1 secretoneurin levels and 90-day mortality in patients with severe sepsis without shock was attenuated and no longer significant in multivariate analysis (Table 1 , Model number 2). The interaction between secretoneurin concentrations and septic shock for prognosis was also validated by logistic regression models (Supplementary Table 6 Table 2) .
Secretoneurin Levels During Hospitalization in Patients With Septic Shock or Severe Sepsis Without Shock and Associations With Outcomes
On average, secretoneurin levels were higher in patients with septic shock compared with patients with severe sepsis without shock during the ICU stay (Supplementary Fig. 2A , Supplemental Digital Content 1, http://links.lww.com/CCM/ D316). Secretoneurin levels did not change significantly during the ICU hospitalization for the two groups of patients, neither in patients randomized to albumin and crystalloid administration nor in the group randomized to crystalloid administration alone (Supplementary Fig. 2B , Supplemental Digital Content 1, http://links.lww.com/CCM/D316).
Secretoneurin levels on day 2 were independently associated with ICU and 90-day mortality in patients with septic shock, but not in those with severe sepsis without shock (Table 1) . This remained true even after robust adjustments for clinical risk factors, with or without further addition of the circulating cardiac biomarkers NT-proBNP and hs-cTnT. In patients with Fig.  3 , Supplemental Digital Content 1, http://links.lww.com/CCM/ D316). The addition of secretoneurin levels on day 2 to the basic models both downgraded risk in survivors and upgraded risk in nonsurvivors ( Supplementary Fig. 3 , Supplemental Digital Content 1, http://links.lww.com/CCM/D316). In patients with septic shock, secretoneurin levels on day 7 were also associated with clinical outcomes by univariate analyses, but did not add prognostic information to established risk indices and biomarkers in multivariable models ( Table 1) . The AUROCs for ICU and 90-day mortality of secretoneurin and established cardiac biomarkers on day 1, 2, and 7 in patients with septic shock are presented in Table 2 . Changes in secretoneurin levels from day 1 to day 2 and from day 2 to day 7 were not associated with ICU or 90-day mortality (Supplementary Table 7 , Supplemental Digital Content 1, http://links.lww.com/ CCM/D316).
DISCUSSION
The principal result of this study is that early secretoneurin measurements in patients with severe sepsis and septic shock provide additional prognostic information to established risk scores and cardiac biomarkers in patients with cardiovascular instability.
The occurrence rate of sepsis seems to be rising in the Western world (14) . Although a number of strategies have been tested (15) , treatment is currently focused on early infectious control and optimal supportive therapy (16), while the mortality rate is still around 30-40%. Given that the principal causes of death in septic patients are multiple organ failure, refractive shock, and respiratory failure (17) , strategies that target these pathophysiologic processes could improve outcome. Furthermore, early diagnosis of specific pathophysiology like myocardial and renal dysfunction will probably be of great importance due to the complex and integrated pathophysiology behind disease progression in septic patients (14, 15) . Pertinent to this point, current guidelines for sepsis emphasizes the early period after sepsis development as the most crucial period to start therapeutic interventions (16) . However, as . Multivariable models number 2: Further addition of highly sensitive cardiac troponin T and N-terminal pro-B-type natriuretic peptide levels, measured on the same day as secretoneurin and entered after natural logarithm transformation, on top of models number 1.
Critical Care Medicine www.ccmjournal.org e409 established risk models like SOFA and SAPS II scores incorporate different pathophysiologic axes into the scoring systems (18, 19) , the ability of these risk models to diagnose specific pathophysiology in individual patients with sepsis and septic shock is reduced. Accordingly, there is a need to develop tools that are easy to use and can detect specific pathophysiology on ICU admission in patients with severe sepsis and septic shock. Secretoneurin is a promising novel biomarker for risk assessment in different populations (5, (7) (8) (9) . Recent studies have found secretoneurin levels to provide incremental prognostic information to established risk indices and biomarkers in different cohorts of patients with myocardial dysfunction (7-9). We have also found strong and independent prognostic information by secretoneurin when measured at ICU admission in two cohorts of critically ill patients with infections, including in patients with severe sepsis and septic shock from the FINNSEPSIS Study (8) . The FINNSEPSIS cohort is comparable with the ALBIOS biomarker substudy cohort, but the blood samples were collected in 2005 in FINNSEPSIS, which is almost 10 years earlier than the samples collected in ALBIOS. Hence, our recent data from the ALBIOS Study validate and expand on the data from FINNSEPSIS in a modern sepsis population with treatment tailored according to the Surviving Sepsis Campaign guidelines (16) . In this and other studies, the correlation coefficients between circulating secretoneurin and hs-cTnT and NT-proBNP levels have been 0.30-0.40, which support the concept of secretoneurin as a biomarker that reflects additional pathophysiology to the established cardiac biomarkers. Circulating secretoneurin concentrations are also influenced by renal dysfunction in septic patients (8) , probably as a result of reduced clearance, and secretoneurin therefore provides prognostic information also by detecting kidney failure. Of relevance for septic patients, the prognostic utility of secretoneurin seems most prominent when measured early after hospital admission (7) (8) (9) . We now validate and expand on these previous results by demonstrating strong and independent prognostic information by secretoneurin when measured on day 1 and day 2 after randomization in septic shock patients from the ALBIOS trial, which is the largest severe sepsis or septic shock cohort with biospecimens. Secretoneurin levels on day 2 after randomization also reclassified a significant proportion of patients into their correct risk strata when added on top of established risk scores and cardiac biomarkers, both by upgrading risk in nonsurvivors and by downgrading risk in survivors. Accordingly, our results support the model of secretoneurin as a biomarker with potential to improve risk assessment in individual patients with sepsis, and especially measurements after 24 hours appear to provide strong prognostic information. Still, as secretoneurin only provided incremental prognostic information in patients with septic shock, the prognostic utility of secretoneurin seems linked to the subgroup of septic patients with hemodynamic instability. This would be in line with previous data from patients hospitalized with acute dyspnea where secretoneurin provided additional prognostic information to established risk indices in patients with cardiovascular-related dyspnea, but not in patients with acute pulmonary disease (7, 9) . However, as we did not find the same difference in prognostic information according to the presence or absence of shock in the FINNSEPSIS Study (8) , additional studies will be required to validate this concept for secretoneurin in patients with septic shock. Of note, differences in the design and execution of the FINNSEPSIS Study and the ALBIOS trial could explain some of the discrepancy for secretoneurin between the two studies. These differences include closer monitoring and reporting of shock in the interventional ALBIOS trial, which tested two strategies for fluid administration, compared with the clinicalepidemiologic FINNSEPSIS Study that had no special focus on fluid administration. FINNSEPSIS also did not have centralized criteria and treatment algorithms for fluid administration, while fluid administration was conducted according to the most updated strategies for early goal-oriented therapy in ALBIOS. Hence, it is plausible that, in general, the patients who developed shock in ALBIOS may have had more severely compromised cardiovascular status compared with the septic shock patients in FINNSEPSIS. It is also conceivable that less stringent early fluid administration and other supportive therapies in FINNSEPSIS may have exposed patients with severe sepsis of that cohort to an increased risk of developing hemodynamic instability, which could explain why secretoneurin concentrations were more closely associated with mortality among severe sepsis patients in FINNSEPSIS compared with severe sepsis patients in ALBIOS trial. Still, the main conclusion of these two large, multicenter studies including patients with severe sepsis and septic shock indicates that secretoneurin concentrations measured early after ICU admission improves risk assessment. Of note, results for AUROC demonstrate some overlap in secretoneurin levels between patients with a favorable and poor prognosis. This is not surprising as patients with septic shock die of a number of different causes, and most biomarkers are reflective only of specific pathophysiology. This study has some limitations and strengths. Although the study represents the largest cohort with blood samples from patients with severe sepsis and septic shock currently available, it is a substudy of an interventional trial, and our results may not be representative for the overall population of patients with sepsis across different ICUs. Still, as the patients with blood samples demonstrated similar clinical characteristics as the overall ALBIOS population, we believe that this may not be a major problem. Mortality rates among the different groups in the ALBIOS Study were also in the same range as mortality rates previously reported in other cohorts and centers, including mortality rates in epidemiologic studies like FINNSEPSIS (20) . Unfortunately, cardiac imaging was not available from the patients in the ALBIOS Study, and this is a limitation to the current substudy. Of note, as previous reports in patients with heart failure have not found secretoneurin to correlate with specific echocardiographic indices of myocardial function (5, 7), it is unlikely that secretoneurin can be used as a surrogate marker for echocardiographic indices in patients with severe sepsis or septic shock. To the contrary, secretoneurin provides additional information also to echocardiographic indices of myocardial function (5, 7) ; thus, potential future use of secretoneurin as risk marker in septic patients will not replace but rather complement imaging methods of myocardial function. For this specific study, we did not include an external validation cohort, but rather this report should be considered complementary to previous data of strong prognostic value of secretoneurin in two cohorts of critically ill patients with infections (8).
In conclusion, secretoneurin provides complementary information to established risk models and cardiac biomarkers in patients with septic shock, which suggests that secretoneurin primarily may be of use in septic patients with cardiovascular instability. In contrast, the prognostic utility of secretoneurin in septic patients without cardiovascular instability seems more limited.
